Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis

• Status: Unknown status
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators will use PET and 11C-Flumazenil to visualize and quantify neuronal injury in the cortex and the deep gray matter of Multiple Sclerosis patients at an early stage. The investigators will follow up patients to determine the prognostic value of this neuronal injury.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Flumazenil

Criteria

Inclusion Criteria:

Four groups of subjects will be included:

• patients with a RRMS evolving since less than 5 years (revised Mc Donald criteria, n=20);

• patients with a RRMS evolving since more than 5 years and less than 10 years (n=20);

• patients with a primary progressive MS (PPMS) evolving since less than 10 years (n=20);

• Healthy volunteers matched for age and sex (2/3 matched with RRMS patients; 1/3 matched with PPMS patients).

Exclusion Criteria:

• Lack of social insurance

• Pregnancy

• Age > 55

• Therapy with benzodiazepine